Bystander Effect of Oncothermia

Figure 9

TRAIL detection IHCH from TMA multiblock. TRAIL (DR5) is a higly immunogenic cell surface receptor. Expression was increased in the treated side 8 h after the treatment and became more emphasized after 14 h.